Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 164   

Articles published

NVS 95.60 +0.92 (0.97%)
price chart
Novartis AG (ADR) Partners With Amgen, Inc. On Alzheimer's And Migraine
Amgen, Inc. (NASDAQ:AMGN) entered into a two-way partnership deal with Novartis AG (ADR) (NYSE:NVS) on Tuesday, to co-develop the Swiss drug-maker's Alzheimer's drug pipeline, in exchange for Novartis gaining access to Amgen's migraine drug ...
Novartis AG (ADR) (NYSE:NVS) Revolade Gets EU Nod
Novartis AG (ADR) (NYSE:NVS) the oncology drug maker is now all set to market key Severe Aplastic Anemia (SAA) drug, Revolade in Europe soon.
Stock Report on Novartis AG (ADR) (NYSE:NVS)
[CNW Group] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS).
Novartis AG (ADR) (NYSE:NVS) Mereo BioPharma Group Ltd
Novartis AG (ADR) (NYSE:NVS) would continue to hold a stake in the success of the three compounds which it will spin-off to Mereo BioPharma for further development.
Scorching Stocks in Action- Novartis AG (NYSE:NVS), Cabot Oil & Gas ...  StreetWise Report
News Highlights: Novartis AG (NYSE:NVS), Keryx Biopharmaceuticals Inc ...  eMarketsDaily
Novartis AG (ADR) (NYSE:NVS) Announced Second Quarter Earnings
[Capital Cube] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) reports preliminary financial results for the quarter ended June 30, 2015.
Technical Report on Novartis AG (ADR) (NYSE:NVS)
[Zacks] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced positive one-year results from a pivotal multi-center, randomized, placebo-controlled phase III study (FUTURE 2) on Cosentyx.
Novartis AG (ADR) (NYSE:NVS) Faces a Huge Fine as a Result of Allegations ...
Will Novartis AG (ADR) Buy Pfizer Inc. Biosimilar Remicade?
Pfizer Inc. (NYSE:PFE) nears the completion of its $16 billion acquisition of Hospira Inc. (NYSE:HSP). The deal, which was agreed upon by the two parties in February, secured approval from the European regulators earlier this week, and now awaits ...
Novartis AG (ADR) Declines As Merck andamp; Co., Wins Patent Battle
Novartis AG ADR (NYSE:NVS) declined 2.3% during yesterday's trade as the company lost a patent battle to Merck & Co.
Stock Insights on Novartis AG (ADR) (NYSE:NVS)
[Bloomberg] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) The U.S. is seeking as much as $3.3 billion from Novartis AG in a suit claiming the company paid kickbacks to increase sales of two prescription drugs.
Novartis AG (ADR) (NVS) To Acquire Spinifex
Novartis AG (ADR) (NYSE:NVS) has announced the acquisition of Spinifex Pharmaceuticals, Inc. The acquisition will allow Novartis to gain access to Spinifex's experimental drugs for chronic pain.
Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million  Bidness ETC
Novartis to buy privately held Spinifex for $200 mln  Proactive Investors USA & Canada